Viventia Biotech Inc.

The central focus of our business strategy is to discover and develop multiple lead products which we intend to advance through to at least the completion of Phase II clinical trials. If any of our therapies complete Phase II trials, we intend to either finance further clinical development ourselves, or enter into strategic partnerships whereby third parties will finance further clinical development, such as Phase III clinical trials. Ultimately, should our products demonstrate sufficient clinical benefit to obtain regulatory approval for marketing, we will seek third parties as partners to market, sell and distribute such products.